Amicus Therapeutics, Inc. (NASDAQ:FOLD)

CAPS Rating: 2 out of 5

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.

Recs

2
Player Avatar zzlangerhans (99.77) Submitted: 2/22/2013 6:28:09 PM : Outperform Start Price: $2.76 FOLD Score: -42.62

I wasn't quite ready to green thumb Amicus again but I'm going to defer to Portefeuille here, who tells me that this is a good time to get into the stock. I may be the score leader, but Portefeuille is definitely the king of making money on this stock. He's been right more times than I can remember, and I think Amicus is responsible for more gains in his fund than any other stub.

Personally, I've come to think of Amicus as a perma-disappointer yet the company has influential supporters including Feuerstein, and they seem to get a never=ending supply of second and third chances. The share price is back close to the one year low after the company reported disappointing data from analysis of secondary six month endpoints of Study 011 of Amigal in Fabry's disease. That disappointment follows an even more surprising disappointment in December after failure to meet the primary endpoint. But it looks like Study 011 will get a third chance, as twelve month data is expected in late Q2 and the company has held out the carrot of a post-hoc subset analysis showing a more pronounced effect of Amigal in more severe disease.

After booking cash from the GSK deal and a judicious dilutive financing at a higher share price, Amicus will likely boast a year end cash position of about 95M to justify a 138M cap. An enterprise value of 40M isn't unreasonable if Amigal still has a chance at the 500M Fabry's market. My style would be to give the stock more time to settle, but every time I've failed to follow Portefeuille's advice on this stock before I've been wrong. It'll be interesting to see how this pick turns out.

Report this Post 3 Replies
Member Avatar zzlangerhans (99.77) Submitted: 2/26/2013 3:00:11 PM
Recs: 2

Oops, forgot to update my 5000 share buy at 2.74 on 2/25/13. Following Portefeuille's recommendation with real money.

Member Avatar zzlangerhans (99.77) Submitted: 3/12/2013 1:21:53 PM
Recs: 2

Just sold 1500 shares at 3.13 for a profit of $570 for the Portefeuille account.

Member Avatar zzlangerhans (99.77) Submitted: 3/13/2013 2:24:54 PM
Recs: 2

Just sold 1500 shares at 3.29 for a profit of $825 for the Portefeuile account.

Featured Broker Partners


Advertisement